SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Athersys Preps MultiStem® Stroke Therapy for Approval Under Japan’s RegenMed Law
When Japan’s landmark regenerative medicine legislation took effect in 2014, it opened an entirely new market for biotech innovators. Athersys, a leader in regenerative medicine, seized the opportunity.
October 28, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Update – COVID-19 by the Numbers: Excess Deaths Remain High, but are Declining
Excess mortality rates in the U.S. remain high, despite a steady decline since mid-December.
October 27, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Catalent Boosts Supply Chain Transparency in Response to COVID-19 Manufacturing Urgency
The pharmaceutical supply chain is being pushed to its limit as it prepares to deliver COVID-19 vaccines and therapeutics to the entire world as soon as possible, while continuing to produce and deliver all the usual medications and products.
October 23, 2020
 · 
4 min read
 · 
Gail Dutton
Business
FDA Deputy Commissioner Discusses Modernization Strategies for Data and Trials
After reviewing its mid-pandemic performance, it became clear that its greatest challenge is around the handling of data, according to Amy P. Abernethy, M.D., Ph.D., principal deputy commissioner, FDA, speaking at the recent Demy-Colton Virtual Salon, the “Fusion of Technologies.”
October 22, 2020
 · 
4 min read
 · 
Gail Dutton
Job Trends
How Kite is Building its CAR-T Franchise Despite COVID-19 Restrictions
Kite, a Gilead company, is building a franchise, not just a brand, on the promise of its CAR-T cell therapies.
October 20, 2020
 · 
5 min read
 · 
Gail Dutton
Extracellular vesicle therapies are gaining moment
Business
Disruptive Technologies and Mature Regulatory Environment Vital for Cell Therapy Maturation
Immuno-oncology and CAR T cells energized the field of regenerative medicine, but for cell and gene to deliver on their promises, new, disruptive technologies and new modes of operation are needed.
October 16, 2020
 · 
5 min read
 · 
Gail Dutton
Pavel Metluk/Shutterstock
Policy
CDC Finalizes COVID-19 Vaccine Distribution Plan as Vaccine Authorization Nears
With multiple COVID-19 vaccines in development, the CDC is confident that any vaccines the FDA authorizes or approves will be safe because they are based on the FDA’s usual stringent protocols. The greater question, after a vaccine is approved, is how it will be distributed.
October 14, 2020
 · 
4 min read
 · 
Gail Dutton
Drug Development
Femtech Trailblazers Talk Innovation and Capitalization to Meet Women’s Underserved Needs
Femtech represents significant growth opportunities for biotech companies, but is still under the radar for most investors. None-the-less, pioneering companies are emerging to address this sector’s many underserved needs.
October 13, 2020
 · 
5 min read
 · 
Gail Dutton
Policy
Innovent and Eli Lilly Gain Approval to Market Halpryza® in China
Innovent and Lilly expect Halpryza to be a high quality and slightly more affordable rituximab injection for a market experiencing serious needs.
October 12, 2020
 · 
4 min read
 · 
Gail Dutton
Courtesy of artjazz/Getty Images
Policy
EU Faces Remdesivir Shortages Amidst Sharp Spikes in New COVID-19 Cases
Supplies of remdesivir are running out across Europe, leading to rationing and reliance on the generic drug, dexamethasone. The UK rationed its supplies of remdesivir Tuesday in the face of rising demands.
October 9, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Pfizer-Lilly Endeavor Shows NGF Inhibitor Tanezumab Lowers Osteoarthritic Pain
Results from multiple Phase III trials show consistent improvements in pain relief and physical function.
October 8, 2020
 · 
4 min read
 · 
Gail Dutton
Deals
10x Genomics Enters In Situ Analysis Market with Recent Acquisitions
10X Genomics just agreed to acquire ReadCoor, Inc., an innovator in the nascent field of in situ technology. The $350 million deal comes on the heels of 10x Genomics’ August acquisition of CartaNA AB, a Stockholm-based developer of in situ RNA analysis technology.
October 8, 2020
 · 
3 min read
 · 
Gail Dutton
Drug Development
Fluorescent Quantum Dot Tool Lets Researchers Study SARS-CoV-2 Without Risk of Infection
A new, nanoparticle tool mimics the way the SARS-CoV-2 virus infects a cell, letting scientists perform vital COVID-19 research without the risk of becoming infected themselves.
October 7, 2020
 · 
4 min read
 · 
Gail Dutton
Business
First Statewide, Random Sample Study of COVID-19 Fatality IDs Risk by Age, Gender and Ethnicity
The probability of dying from COVID-19 depends more on age than gender, race or ethnicity, according to the first U.S. statewide random sample study of SARS-CoV-2 prevalence and fatalities.
October 6, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Grace Wei’s Journey from Academia to Encellin Co-Founder and Entrepreneur
Grace Wei, Ph.D., who founded Encellin in 2016 with co-founder Crystal Nyitray, Ph.D., shared some of her lessons during a recent Innovation Centre Denmark, Silicon Valley presentation for would-be biotech entrepreneurs.
October 5, 2020
 · 
3 min read
 · 
Gail Dutton
Load More